Overview
Torsten Dreier co-founded argenx in 2008 in Ghent alongside Tim Van Hauwermeiren and Hans de Haard, having previously worked together at Ablynx. He has more than 20 years of antibody development experience and progressed six antibody products from preclinical research into clinical trials. At Ablynx he held roles as Director of Therapeutic Drug Development and Senior Director Preclinical Development.
Career history
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.